Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

Middle area:

Key facts & figures

Sanofi is a global healthcare company focused on patient needs. Our business includes pharmaceuticals (notably prescription drugs for diabetes, rare diseases, multiple sclerosis and oncology, consumer healthcare products and generics), vaccines and animal health.

Solid financial performance

2015 Aggregate Group Sales*
€37,057m

+9.7% on a reported basis 
+2.2% at constant exchange rates (CER)

2015 Business EPS
€5.64

+8.5% on a reported basis
stable at CER

 

*including Animal Health Business which is reported on a single line in the consolidated income statements in accordance with IFRS 5 (Non-current assets held for sale and discontinued operations)
 

GENZYME, VACCINES AND ANIMAL HEALTH DROVE SALES GROWTH IN 2015

2015 aggregate sales by business areas
2015 aggregate sales by business areasChange at CER
Pharmaceuticals€29,799M+0.8%
Diabetes€7,580M-6.8%
Genzyme€3,664M+29.5%
Oncology€1,504M-1.9%
Consumer Healthcare€3,492M+2.8%
Established Products€11,633M-2.3%
Generics€1,917M+7.6%
Vaccines€4,743M+7.3%
Animal Health€2,515M+10.8%
 

Executing on 2020 strategic roadmap

Key milestones in reshaping the portfolio

with announcement of exclusive negotiations on business swap with Boehringer Ingelheim

Significant R&D alliances

in oncology and diabetes

Praluent® launch

progressing with significant U.S. market access for 2016

Toujeo® available globally

in over 20 countries, reaching sales of €98 million in Q4 2015

 
 

© Sanofi 2004-2016 - All rights reserved - Update: February 11, 2016

  • Site complies with W3C WCAG 2.0 (new window, in english)